GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avenue Therapeutics Inc (NAS:ATXI) » Definitions » Price-to-Tangible-Book

Avenue Therapeutics (Avenue Therapeutics) Price-to-Tangible-Book : 0.70 (As of Jun. 07, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Avenue Therapeutics Price-to-Tangible-Book?

As of today (2024-06-07), Avenue Therapeutics's share price is $3.38. Avenue Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $4.81. Hence, Avenue Therapeutics's Price to Tangible Book Ratio of today is 0.70.

The historical rank and industry rank for Avenue Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

ATXI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.7   Med: 7.92   Max: 68.94
Current: 0.7

During the past 9 years, Avenue Therapeutics's highest Price to Tangible Book Ratio was 68.94. The lowest was 0.70. And the median was 7.92.

ATXI's Price-to-Tangible-Book is ranked better than
89.41% of 1218 companies
in the Biotechnology industry
Industry Median: 2.79 vs ATXI: 0.70

A closely related ratio is called PB Ratio. As of today, Avenue Therapeutics's share price is $3.38. Avenue Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $4.81. Hence, Avenue Therapeutics's P/B Ratio of today is 0.70.


Avenue Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Avenue Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avenue Therapeutics Price-to-Tangible-Book Chart

Avenue Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only 23.55 42.25 5.55 1.42 2.61

Avenue Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 2.61 2.30

Competitive Comparison of Avenue Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Avenue Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avenue Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Avenue Therapeutics's Price-to-Tangible-Book falls into.



Avenue Therapeutics Price-to-Tangible-Book Calculation

Avenue Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=3.38/4.805
=0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Avenue Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Avenue Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Avenue Therapeutics (Avenue Therapeutics) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule for CNS diseases, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
Executives
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Fortress Biotech, Inc. 10 percent owner 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Invagen Pharmaceuticals, Inc. 10 percent owner SITE B, 7 OSER AVE., HAUPPAUGE NY 11788
Alexandra Maclean officer: Chief Executive Officer C/O AVENUE THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NC 10014
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
David Jin officer: Int. PEO, Int. PFO, and COO C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Joseph Walter Vazzano officer: Chief Financial Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Curtis Gale Oltmans director C/O ARRAY BIOPHARMA INC., 3200 WALNUT ST., BOULDER CO 80301
Jay D Kranzler director 4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO CA 92121
Lucy Lu director, officer: President, CEO THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elizabeth Garrett Ingram director 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Thomas Gregory Moore director C/O AKORN, INC., 1925 WEST FIELD COURT, SUITE 300, LAKE FOREST IL 60045
Nishant Saxena director CIPLA HOUSE, PENINSULA BUSINESS PARK, LOWER PAREL, MUMBAI K7 400013
Jaideep Ashok Gogtay director CIPLA LTD., MUMBA CENTRAL, BESIDE CITY CENTER, MUMBAI K7 400008